Psychosomatic aspects of psoriasis (review)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The review reflects the increased scientific interest in the psychosomatic aspects of psoriasis in the world literature in recent years. The studied material of the articles is structured according to the principles of the modern clinical psychosomatic approach. The introduction substantiates the relevance of studying this topic. The article considers the stress manifestations/examinations of psoriasis under the influence of psychosocial acute and chronic stress, including under the action of the COVID-19 pandemic; the quality of life and stigmatization of patients with psoriasis. The driving factors leading to the formation of nosogenic psychosomatic disorders are identified: common disfiguring rashes, itching, recurrent course, the threat of disability, social restrictions, constitutional premorbid features of patients. The description of comorbid mental disorders of the anxiety and affective range with a discussion of suicidal risk is presented. A separate section of the review is devoted to itching, as one of the most discussed aspects of psoriasis in the modern literature. Different points of view on the psycho-biological structure of itching in psoriasis are presented. Various factors related to the intensity, objective and subjective perception of itching are considered. Among them are the clinical form and severity of psoriasis, the localization and prevalence of rashes, gender, age, level of education, marital status of patients, concomitant somatic and mental diseases.

About the authors

Igor Yu. Dorozhenok

The First Sechenov Moscow State Medical University (Sechenov University); Mental Health Research Center of the Russian Academy of Medical Sciences

Author for correspondence.
Email: idoro@bk.ru
ORCID iD: 0000-0003-1613-2510
SPIN-code: 8701-7958
Scopus Author ID: 35773056200
ResearcherId: S-4709-2016

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, 2 building 2 st. Bolshaya Pirogovskaya, 119992, Moscow; Moscow

Ekaterina V. Ilina

The First Sechenov Moscow State Medical University (Sechenov University)

Email: ekaterinailina19962@gmail.com
ORCID iD: 0000-0003-0091-4294

Clinical Resident

Russian Federation, 2 building 2 st. Bolshaya Pirogovskaya, 119992, Moscow

References

  1. Olisova O, Garanyan L. Epidemiology, etiopathogenesis, comorbidity in psoriasis ― new facts. Russian Journal of Skin and Venereal Diseases. 2017;20(4):214–219. (In Russ). doi: 10.18821/1560-9588-2017-20-4-214-219
  2. Parisi R, Symmons D, Griffiths C, Ashcroft D. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi: 10.1038/jid.2012.339
  3. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi: 10.1016/j.jaad.2016.07.064
  4. Kwon CW, Fried RG, Nousari Y, et al. Psoriasis: Psychosomatic, somatopsychic, or both? Clin Dermatol. 2018;36(6):698–703. doi: 10.1016/j.clindermatol.2018.08.009
  5. Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. doi: 10.3390/ijms20184347
  6. Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat. 2018;29(5):487–495. doi: 10.1080/09546634.2017.1395800
  7. Ferreira BI, Abreu JL, Reis JP, Figueiredo AM. Psoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlation. J Clin Aesthet Dermatol. 2016;9(6):36–43.
  8. Patel KR, Lee HH, Rastogi S, et al. Association of psoriasis with psychiatric hospitalization in United States children and adults. Dermatology. 2019;235(4):276–286. doi: 10.1159/000499564
  9. Bolotna L, Sarian O. Psychopathological disorders as comorbidity in patients with psoriasis (review). Georgian Med News. 2020;(301):143–147.
  10. Lim DS, Bewley A, Oon HH. Psychological profile of patients with psoriasis. Ann Acad Med Singap. 2018;47(12):516–522.
  11. Korkoliakou P, Efstathiou V, Giannopoulou I, et al. Psychopathology and alexithymia in patients with psoriasis. An Bras Dermatol. 2017;92(4):510–515. doi: 10.1590/abd1806-4841.20175660
  12. Zeidler C, Pereira MP, Huet F, et al. Pruritus in autoimmune and inflammatory dermatoses. Front Immunol. 2019;10:1303. doi: 10.3389/fimmu.2019.01303
  13. Dickison P, Swain G, Peek JJ, Smith SD. Itching for answers: Prevalence and severity of pruritus in psoriasis. Australas J Dermatol. 2018;59(3):206–209. doi: 10.1111/ajd.12747
  14. Dodoo-Schittko F. Psoriasis: the significance of psychological stress. Br J Dermatol. 2018;178(5):1002. doi: 10.1111/bjd.16472
  15. Hunter HJ, Griffiths CE, Kleyn CE. Does psychosocial stress play a role in the exacerbation of psoriasis? Br J Dermatol. 2013;169(5):965–974. doi: 10.1111/bjd.12478
  16. Basavaraj KH, Navya MA, Rashmi R. Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011;50(7):783–792. doi: 10.1111/j.1365-4632.2010.04844.x
  17. Rousset L, Halioua B. Stress and psoriasis. Int J Dermatol. 2018;57(10):1165–1172. doi: 10.1111/ijd.14032
  18. Pancar Yuksel E, Durmus D, Sarisoy G. Perceived stress, life events, fatigue and temperament in patients with psoriasis. J Int Med Res. 2019;47(9):4284–4291. doi: 10.1177/0300060519862658
  19. Snast I, Reiter O, Atzmony L, et al. Psychological stress and psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2018;178(5):1044–1055. doi: 10.1111/bjd.16116
  20. Lada G, Talbot PS, Bewley A, Kleyn CE. Mental health and dermatology practice in the COVID-19 pandemic. Clin Exp Dermatol. 2020;45(7):816–817. doi: 10.1111/ced.14330
  21. Ozaras R, Berk A, Ucar DH, et al. Covid-19 and exacerbation of psoriasis. Dermatol Ther. 2020;33(4):e13632. doi: 10.1111/dth.13632
  22. Karavaeva TA, Korol’kova TN. Psychological mechanisms and psychosomatic relationships in various dermatoses. Clinical Dermatology and Venereology. 2018;17(5):7–17. (In Russ). doi: 10.17116/klinderma2018170517
  23. Ruzhinskikh AG, Solovjeva SL. Personality and psychological characteristics traits of patients with various degrees of severity of psoriasis. Neurology Bulletin. 2016;48(3):25–33. (In Russ).
  24. Gisondi P. High prevalence of alcohol use disorders in patients with inflammatory skin diseases applies to both psoriasis and eczema. Br J Dermatol. 2017;177(3):606–607. doi: 10.1111/bjd.15674
  25. Jankowiak B, Kowalewska B, Krajewska-Kułak E, et al. Relationship between self-esteem and stigmatization in psoriasis patients. Postepy Dermatol Alergol. 2020;37(4):597–602. doi: 10.5114/ada.2020.93242
  26. Pashinyan AG, Dvornikov AS, Doncova EV. Assessing the quality of life of patients with psoriasis: a review of current research. Medical business. 2019;2:32–35. (In Russ). doi: 10.24411/2071-5315-2019-12109
  27. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS One. 2012;7(12):e52935. doi: 10.1371/journal.pone.0052935
  28. Alpsoy E, Polat M, FettahlıoGlu-Karaman B, et al. Internalized stigma in psoriasis: a multicenter study. J Dermatol. 2017;44(8):885–891. doi: 10.1111/1346-8138.13841
  29. Wu JH, Cohen BA. The stigma of skin disease. Curr Opin Pediatr. 2019;31(4):509–514. doi: 10.1097/MOP.0000000000000792
  30. Parkhouse AR. Experiences of stigma-stress among people living with psoriasis in the United States. Am J Health Behav. 2019;43(2):243–257. doi: 10.5993/AJHB.43.2.2
  31. Tee SI, Lim ZV, Theng CT, et al. A prospective cross-sectional study of anxiety and depression in patients with psoriasis in Singapore. J Eur Acad Dermatol Venereol. 2016;30(7):1159–1164. doi: 10.1111/jdv.13615
  32. Korkoliakou P, Efstathiou V, Giannopoulou I, et al. Psychopathology and alexithymia in patients with psoriasis. An Bras Dermatol. 2017;92(4):510–515. doi: 10.1590/abd1806-4841.20175660
  33. Bangemann K, Schulz W, Wohlleben J, et al. Depression and anxiety disorders among psoriasis patients: protective and exacerbating factors. Hautarzt. 2014;65(12):1056–1061. doi: 10.1007/s00105-014-3513-9
  34. Alariny AF, Farid CI, Elweshahi HM, Abbood SS. Psychological and sexual consequences of psoriasis vulgaris on patients and their partners. J Sex Med. 2019;16(12):1900–1911. doi: 10.1016/j.jsxm.2019.08.017
  35. Fleming P, Bai JW, Pratt M, et al. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol. 2017;31(5):798–807. doi: 10.1111/jdv.13891
  36. Kwan Z, Bong YB, Tan LL, et al. Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res. 2018;310(5):443–451. doi: 10.1007/s00403-018-1832-x
  37. Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population: national health and nutrition examination survey 2009–2012. JAMA Dermatol. 2016;152(1):73–79. doi: 10.1001/jamadermatol.2015.3605
  38. Lamb RC, Matcham F, Turner MA, et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol. 2017;176(4):1028–1034. doi: 10.1111/bjd.14833
  39. Singh S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and suicidality: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425–440.e2. doi: 10.1016/j.jaad.2017.05.019
  40. Egeberg A, Hansen PR, Gislason GH, et al. Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2016;175(3):493–500. doi: 10.1111/bjd.14633
  41. Gupta MA, Pur DR, Vujcic B, Gupta AK. Suicidal behaviors in the dermatology patient. Clin Dermatol. 2017;35(3):302–311. doi: 10.1016/j.clindermatol.2017.01.006
  42. Kaufman KR. Etanercept, anticytokines and mania. Int Clin Psychopharmacol. 2005;20(4):239–241. doi: 10.1097/00004850-200507000-00008
  43. Komiya E, Tominaga M, Kamata Y, et al. Molecular and cellular mechanisms of itch in psoriasis. Int J Mol Sci. 2020;21(21):8406. doi: 10.3390/ijms21218406
  44. Elewski B, Alexis AF, Lebwohl M, et al. Itch: an under-recognized problem in psoriasis. J Eur Acad Dermatol Venereol. 2019;33(8):1465–1476. doi: 10.1111/jdv.15450
  45. Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol. 2014;70(2):390–391. doi: 10.1016/j.jaad.2013.09.030
  46. Szepietowski JC, Reich A. Pruritus in psoriasis: An update. Eur J Pain. 2016;20(1):41–46. doi: 10.1002/ejp.768
  47. Mrowietz U, Chouela EN, Mallbris L, et al. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol. 2015;29(6):1114–1120. doi: 10.1111/jdv.12761
  48. Jafferany M, Davari ME. Itch and psyche: psychiatric aspects of pruritus. Int J Dermatol. 2019;58(1):3–23. doi: 10.1111/ijd.14081
  49. Zhu B, Edson-Heredia E, Guo J, et al. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. Br J Dermatol. 2014;171(5):1215–1219. doi: 10.1111/bjd.13065
  50. Bundy C, Borthwick M, McAteer H, et al. Psoriasis: snapshots of the unspoken: using novel methods to explore patients’ personal models of psoriasis and the impact on well-being. Br J Dermatol. 2014;171(4):825–831. doi: 10.1111/bjd.13101
  51. Bakulev AL. Psoriasis: clinical features, risk factors and associated comorbid conditions. Clinical Pharmacology and Therapy. 2019;28(1):35–39. (In Russ). doi: 10.32756/0869-5490-2019-1-35-39
  52. Damiani G, Cazzaniga S, Conic RR, Naldi L; Psocare Registry Network. Pruritus characteristics in a large italian cohort of psoriatic patients. J Eur Acad Dermatol Venereol. 2019;33(7):1316–1324. doi: 10.1111/jdv.15539
  53. Bahali AG, Onsun N, Su O, et al. The relationship between pruritus and clinical variables in patients with psoriasis. An Bras Dermatol. 2017;92(4):470–473. doi: 10.1590/abd1806-4841.20175402
  54. Mansouri S, Ebongo C, Benzekri L, et al. Factors predicting pruritus in psoriasis. Presse Med. 2019;48(5):580–581. doi: 10.1016/j.lpm.2019.02.016
  55. Gupta MA, Gupta AK, Schork NJ, Ellis CN. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med. 1994;56(1):36–40. doi: 10.1097/00006842-199401000-00005
  56. Czarnecka-Operacz M, Polańska A, Klimańska M, et al. Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations. Postepy Dermatol Alergol. 2015;32(6):426–430. doi: 10.5114/pdia.2015.56097
  57. Reich A, Hrehorów E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol. 2010;90(3):257–263. doi: 10.2340/00015555-0851
  58. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Psoriasis-associated itch: etiology, assessment, impact, and management. J Dermatolog Treat. 2020;31(1):18–26. doi: 10.1080/09546634.2019.1572865
  59. Nikolaevskaya AO, Alekhina EA. Clinical psychology and health psychology. Siberian Psychological Journal. 2018;69:100–112. (In Russ). doi: 10.17223/17267080/69/6
  60. Stumpf A, Schneider G, Ständer S. Psychosomatic and psychiatric disorders and psychologic factors in pruritus. Clin Dermatol. 2018;36(6):704–708. doi: 10.1016/j.clindermatol.2018.08.015

Copyright (c) 2021 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies